Ser554
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser554  -  LARP (human)

Site Information
AsLPDLDsENWIEVK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15721031

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 )
Disease tissue studied:
lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , lymphoma ( 2 ) , Burkitt's lymphoma ( 2 ) , follicular lymphoma ( 2 ) , mantle cell lymphoma ( 2 )
Relevant cell line - cell type - tissue:

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

5

Possemato A (2010) CST Curation Set: 9255; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info